Cipla Limited (BOM:500087)
India · Delayed Price · Currency is INR 1,353.85
-1.95 (-0.14%)
At close: Jun 19, 2026
Cipla Revenue
In the fiscal year ending March 31, 2026, Cipla had annual revenue of 278.28B INR with 2.06% growth. Cipla had revenue of 65.80B in the quarter ending March 31, 2026, a decrease of -2.07%.
Revenue
278.28B
Revenue Growth
+2.06%
P/S Ratio
4.11
Revenue / Employee
8.87M
Employees
31,369
Market Cap
1.14T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 278.28B | 5.60B | 2.06% |
| Mar 31, 2025 | 272.67B | 17.31B | 6.78% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dr. Reddy's Laboratories | 335.93B |
| Lupin | 279.58B |
| Torrent Pharmaceuticals | 139.80B |
| Jubilant Pharmova | 82.80B |
| Abbott India | 69.29B |
| Granules India | 53.66B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| GlaxoSmithKline Pharmaceuticals | 38.22B |
Cipla News
- 19 hours ago - Pharma sector stocks trade mixed on June 22: Cipla up 2.23%, Indoco Remedies gains 2.38%, Wockhardt falls 1.41% - Business Upturn
- 19 hours ago - Pharma sector stocks today on June 22: Cipla up 2.23%, Indoco Remedies gains 2.38%, Wockhardt falls 1.41% - Business Upturn
- 4 days ago - Cipla advertises Reactin Plus, FDA says recall stock in state - The Times of India
- 5 days ago - Pharma sector stocks today, June 17: Aurobindo Pharma gains 2.26%, Panacea Biotech falls 1.80%, Cipla down 0.32% - Business Upturn
- 6 days ago - Cipla appoints Shivam Puri as CEO of One India Business effective 1st July 2026 - Business Upturn
- 11 days ago - Cipla's Goa facility receives VAI classification from USFDA - Business Upturn
- 13 days ago - Cipla corrects e-voting end date for 90th AGM to 24th June 2026 - Business Upturn
- 13 days ago - Pharma stocks in focus: Nomura highlights strong Zydus growth, Lupin and Cipla see sales decline in April - Business Upturn